William Blair Reiterates “Market Perform” Rating for Altimmune (NASDAQ:ALT)

Altimmune (NASDAQ:ALT)‘s stock had its “market perform” rating reaffirmed by research analysts at William Blair in a research note issued to investors on Friday,RTT News reports.

Other equities analysts have also recently issued reports about the company. Stifel Nicolaus initiated coverage on Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Monday, March 3rd. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Altimmune has a consensus rating of “Moderate Buy” and a consensus target price of $20.83.

Altimmune Price Performance

Shares of ALT opened at $5.92 on Friday. The business’s fifty day moving average price is $6.48 and its 200 day moving average price is $7.11. Altimmune has a 12-month low of $5.14 and a 12-month high of $11.16. The stock has a market capitalization of $455.92 million, a PE ratio of -3.82 and a beta of 0.87.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. As a group, research analysts anticipate that Altimmune will post -1.35 earnings per share for the current fiscal year.

Insider Activity at Altimmune

In related news, CFO Gregory L. Weaver acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were acquired at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Altimmune

A number of hedge funds and other institutional investors have recently modified their holdings of ALT. Ameriprise Financial Inc. raised its stake in shares of Altimmune by 35.6% during the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company’s stock valued at $37,888,000 after purchasing an additional 1,378,854 shares in the last quarter. Bellevue Group AG grew its holdings in Altimmune by 43.9% during the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after acquiring an additional 263,660 shares during the period. Invesco Ltd. grew its holdings in Altimmune by 679.2% during the fourth quarter. Invesco Ltd. now owns 247,086 shares of the company’s stock worth $1,781,000 after acquiring an additional 215,375 shares during the period. Millennium Management LLC grew its holdings in Altimmune by 139.8% during the fourth quarter. Millennium Management LLC now owns 345,637 shares of the company’s stock worth $2,492,000 after acquiring an additional 201,484 shares during the period. Finally, Two Sigma Investments LP grew its holdings in Altimmune by 33.2% during the fourth quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock worth $4,364,000 after acquiring an additional 151,001 shares during the period. 78.05% of the stock is currently owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.